Browsing by Author Raal, Frederick J

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2014Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trialsSullivan, David; et al, Various; Giugliano, Robert P; Kim, Jae; Koren, Michael J; Raal, Frederick J; Roth, Eli M; Somaratne, Ransi; Stein, Evan; Wasserman, Scott M; Weiss, Robert; School of Public Health: NH&MRC Clinical Trials CentreEfficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials, European Heart Journal, vol.35, 33, 2014,pp 2249-2259
2017Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemiaSullivan, David; Bridges, Ian; Coll, Blai; Dent, Ricardo; Descamps, Oliver; Hovingh, G Kees; Lira, Armando; Masana, Luis; Raal, Frederick J; Stefanutti, Claudia; NH&MRC Clinical Trials CentreLong-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia, Journal of Clinical Lipidology, vol.11, 6, 2017,pp 1448-1457
2015PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialSullivan, David; Bridges, Ian; Burgess, Leslie; Cariou, B; Civeira, Fernando; Dufour, Robert; Gaudet, Daniel; Gouni-Berthold, Ioanna; Hovingh, G Kees; Langslet, Gisle; Olsson, Anders; Raal, Frederick J; Scott, Rob; Scott, Russell; Somaratne, Ransi; Stein, Evan; Turner, Traci; Wasserman, Scott M.; NH&MRC Clinical Trials CentrePCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, The Lancet, vol.385, 9965, 2015,pp 331-340